8. Heart Failure (Maria's Part II)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/21

flashcard set

Earn XP

Description and Tags

Vocabulary practice flashcards covering goal-directed medical therapy, ACC/AHA stages, NYHA functional classes, ejection fraction categories, and pharmacology for heart failure.

22 Terms

1
New cards

Goals of Heart Failure Treatment

The three overarching clinical objectives: improving symptoms to maintain functional capabilities and quality of life, reducing hospitalizations, and improving overall survival.

2
New cards

Goal Directed Medical Therapy (GDMT)

An evidence-based medication regimen recommended by clinical guidelines for outpatient heart failure management, primarily selected according to left ventricular ejection fraction.

3
New cards

The Four Pillars of GDMT

The four medication classes proven to reduce morbidity and mortality in heart failure with reduced ejection fraction: ARNIs (or ACE inhibitors/ARBs), beta blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors.

4
New cards

Heart Failure Phenotype

The observable clinical pattern and presentation of a patient based on ejection fraction, cardiac function, cardiac structure, and associated comorbidities.

5
New cards

ACC/AHA Stage A

Patients who are at risk for heart failure but have not yet developed structural heart disease or symptoms of heart failure.

6
New cards

ACC/AHA Stage B

Pre-heart failure defined by the presence of structural heart disease without any prior or current symptoms of heart failure.

7
New cards

ACC/AHA Stage C

Established heart failure characterized by structural heart disease with current or prior symptoms.

8
New cards

ACC/AHA Stage D

Advanced heart failure characterized by refractory symptoms that interfere with daily life and require advanced interventions such as LVAD placement, heart transplantation, or hospice care.

9
New cards

NYHA Functional Class I

A classification where cardiac disease causes no limitation of physical activity; ordinary physical activity does not induce symptoms.

10
New cards

NYHA Functional Class II

Slight limitation of physical activity where patients are comfortable at rest, but ordinary physical activities (such as walking outside or walking around a mall) cause fatigue or dyspnea.

11
New cards

NYHA Functional Class III

Marked limitation of physical activity where symptoms occur with less-than-ordinary activity and interfere with basic activities of daily living such as brushing teeth, cooking, or climbing stairs.

12
New cards

NYHA Functional Class IV

Inability to carry out any physical activity without discomfort, with symptoms of heart failure present even at rest.

13
New cards

Heart Failure with Reduced Ejection Fraction (HFrEF)

Heart failure characterized by an ejection fraction of 40%40\% or less, resulting from systolic pump failure that requires quadruple therapy under GDMT.

14
New cards

SGLT2 Inhibitors in Heart Failure

The sole drug class recommended across all ejection fraction ranges (reduced, mildly reduced, and preserved) that decreases hospitalizations through osmotic and natriuretic diuresis.

15
New cards

Hydralazine plus Isosorbide Dinitrate

A vasodilator combination that lowers preload and afterload; used as an alternative for patients unable to tolerate ACE inhibitors/ARBs/ARNIs, or added to improve morbidity and mortality in persistently symptomatic African American patients with NYHA Class III or IV heart failure.

16
New cards

Loop Diuretics (e.g., Furosemide / Lasix, Bumetanide / Bumex)

Workhorse agents that promote rapid elimination of salt and water from the loop of Henle to treat fluid overload and symptoms, with no effect on morbidity or mortality.

17
New cards

Aldosterone Receptor Antagonists / MRAs

Potassium-sparing agents (such as spironolactone and eplerenone) that block aldosterone in the collecting duct to reduce cardiac remodeling and fluid retention while preventing hypokalemia.

18
New cards

Venous Capacitance

The storage volume capacity of the venous vascular bed; expanding this capacity through venodilators decreases ventricular preload by preventing excessive volume return to the heart.

19
New cards

Evidence-Based Beta Blockers for Heart Failure

The only three beta blockers proven in trials to reduce mortality in heart failure: carvedilol, bisoprolol, and metoprolol succinate (specifically excluding metoprolol tartrate).

20
New cards

Digoxin

An inotropic drug that inhibits the sodium-potassium ATPase pump to increase intracellular calcium and contractility while slowing SA/AV node conduction; used for symptom control and atrial fibrillation, but has a narrow therapeutic window and no mortality benefit.

21
New cards

Dobutamine

A short-term intravenous beta-1 receptor agonist that increases myocardial contractility and cardiac output in patients with acute exacerbations or advanced decompensation.

22
New cards

Milrinone

An intravenous bipyridine inotropic agent typically administered as a continuous infusion to manage refractory end-stage heart failure or serve as a bridge to heart transplantation or an LVAD.